Metraipolis › archive › dc_a46adb59128f

HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy — Europe PMC PMID:41188218

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41188218
DOI
10.1038/s41467-[numero omesso]-x
License (as archived)
solo-consultazione
Archived
2026-10-09T22:41:22.536Z
SHA-256 of the archived text
9a24034e3cf145f869f73272d76eb48968b487b42111500d367af7b6fe6f7553
Stable URL of this page
https://metraipolis.com/documento/dc_a46adb59128f

How to cite

HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy — Europe PMC PMID:41188218 — Europe PMC (en), https://europepmc.org/article/MED/41188218 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a46adb59128f (Metraipolis archive dc_a46adb59128f, sha256 9a24034e3cf145f869f73272d76eb48968b487b42111500d367af7b6fe6f7553)
BibTeX
@misc{dca46adb59128f,
  title = {HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy — Europe PMC PMID:41188218},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41188218},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a46adb59128f; sha256 9a24034e3cf145f869f73272d76eb48968b487b42111500d367af7b6fe6f7553},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41188218. Agents can read the archived copy with the MCP tool read_document.